Takeda Pharmaceutical
4502.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥4.51T | ¥4.58T | ¥4.26T | ¥4.03T | ¥3.57T | ¥3.20T |
| Operating income | ¥6.2bn | ¥342.6bn | ¥214.1bn | ¥490.5bn | ¥460.8bn | ¥509.3bn |
| Net income (owners) | −¥152.4bn | ¥107.9bn | ¥144.1bn | ¥317.0bn | ¥230.1bn | ¥376.0bn |
| Total assets | ¥15.51T | ¥14.25T | ¥15.11T | ¥13.96T | ¥13.18T | ¥12.91T |
| Net assets / equity | ¥7.43T | ¥6.94T | ¥7.27T | ¥6.35T | ¥5.68T | ¥5.18T |
| Operating cash flow | ¥1.04T | ¥1.06T | ¥716.3bn | ¥977.2bn | ¥1.12T | ¥1.01T |
| EPS (basic) | ¥-96.75 | ¥68.36 | ¥92.09 | ¥204.29 | ¥147.14 | ¥240.72 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 82 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 82 figures · EDINET |
21 more reports are still being processed.